PRICES include / exclude VAT
download between 0-24 hoursReleased: 2023
ISO 10993-17:2023
ISO 10993-17:2023-Biological evaluation of medical devices-Part 17: Toxicological risk assessment of medical device constituents
Format
Availability
Price and currency
English PDF
Immediate download
230.00 EUR
English Hardcopy
In stock
230.00 EUR
French PDF
Immediate download
230.00 EUR
French Hardcopy
In stock
230.00 EUR
Standard´s number: | ISO 10993-17:2023 |
Pages: | 65 |
Edition: | 2 |
Released: | 2023 |
DESCRIPTION
ISO 10993-17:2023
This document specifies the process and requirements for the toxicological risk assessment of medical device constituents. The methods and criteria used to assess whether exposure to a constituent is without appreciable harm are also specified. The toxicological risk assessment can be part of the biological evaluation of the final product, as described in ISO 10993-1. The process described in this document applies to chemical characterization information obtained in line with ISO 10993-18. When a toxicological risk assessment of either the compositional information or analytical chemistry data (e.g. extractable data or leachable data) are required to determine whether the toxicological risks related to the constituents are negligible or tolerable. The process described in this document is not intended to apply to circumstances where the toxicological risk has been estimated by other means, such as: — constituents, excluding cohort of concern or excluded chemicals, that are present in or extracted from a medical device at an amount representative of patient exposure below a relevant, toxicologically-based reporting threshold (see applicable requirements in ISO 10993-18:2020, Annex E and ISO/TS 21726); — a new or changed medical device for which chemical or biological equivalence has been established with an existing biocompatible or clinically established medical device (see applicable requirements in ISO 10993-18:2020, Annex C). The process described in this document is also not applicable to: — medical device constituents that do not contact the body (e.g. in vitro diagnostics); — biological risks associated with physical interactions of the medical device with the body (i.e. application of mechanical forces, energy or surface morphology, etc.), provided that the chemical exposure is not changed; — active pharmaceutical ingredients of device-drug combination products or biologic components of device-biologic combination products as additional regulatory considerations can apply; — exposure to a particular constituent that arises from sources other than the device, such as food, water or air.
Customers who bought this item also bought
UNE EN ISO 10993-10:2023
Biological evaluation of medical devices - Part 10: Tests for skin sensitization (ISO 10993-10:2021)
Biological evaluation of medical devices - Part 10: Tests for skin sensitization (ISO 10993-10:2021)
Released: 2023-10-18
English PDF
Immediate download
158.40 EUR
English Hardcopy
In stock
158.40 EUR
Spanish PDF
Immediate download
132.00 EUR
Spanish Hardcopy
In stock
132.00 EUR
UNE EN ISO 10993-5:2009
Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity (ISO 10993-5:2009)
Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity (ISO 10993-5:2009)
Released: 2009-12-09
English PDF
Immediate download
120.12 EUR
English Hardcopy
In stock
120.12 EUR
Spanish PDF
Immediate download
100.10 EUR
Spanish Hardcopy
In stock
100.10 EUR
BS EN ISO 13485:2016+A11:2021
Medical devices. Quality management systems. Requirements for regulatory purposes
Medical devices. Quality management systems. Requirements for regulatory purposes
Released: 2021-09-08
English Secure PDF
Immediate download
379.50 EUR
English Hardcopy
In stock
379.50 EUR
English PDF
Immediate download
230.00 EUR
English Hardcopy
In stock
230.00 EUR
French PDF
Immediate download
230.00 EUR
French Hardcopy
In stock
230.00 EUR